TELA Bio (NASDAQ:TELA) Trading 5.3% Higher

Share on StockTwits

Shares of TELA Bio (NASDAQ:TELA) traded up 5.3% on Tuesday . The stock traded as high as $13.13 and last traded at $12.96, 111,819 shares were traded during trading. An increase of 29% from the average session volume of 86,949 shares. The stock had previously closed at $12.31.

A number of equities analysts recently issued reports on TELA shares. JMP Securities initiated coverage on TELA Bio in a report on Tuesday. They issued an “outperform” rating and a $22.00 price target for the company. Canaccord Genuity initiated coverage on shares of TELA Bio in a report on Tuesday. They set a “buy” rating and a $19.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of TELA Bio in a research report on Tuesday. They set a “buy” rating and a $23.00 price objective for the company. Finally, Piper Jaffray Companies started coverage on shares of TELA Bio in a research report on Tuesday. They set an “overweight” rating and a $17.00 price objective for the company.

In other news, Director Matt Zuga purchased 86,121 shares of the business’s stock in a transaction on Friday, November 8th. The shares were bought at an average price of $12.09 per share, with a total value of $1,041,202.89. Also, major shareholder Orbimed Advisors Llc purchased 384,615 shares of the business’s stock in a transaction on Friday, November 8th. The shares were purchased at an average cost of $12.09 per share, for a total transaction of $4,649,995.35.

About TELA Bio (NASDAQ:TELA)

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

Featured Story: What is a balanced fund?

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.